By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

VBL Therapeutics 

6 Jonathan Netanyahu Street

Or Yehuda    60376  Israel
Phone: 97-236-346450 Fax: 97-236-346449


SEARCH JOBS


Industry
Biotechnology






Company News
Israel's VBL Therapeutics (VBLX) Terminates NASDAQ IPO Due To Shareholder Mishap 8/8/2014 11:10:59 AM
VBL Therapeutics Announces Pricing Of Initial Public Offering 7/31/2014 9:01:40 AM
VBL Therapeutics Announces Completion Of Enrollment In Phase 2 Clinical Studies Of VB-201 In Psoriasis And Ulcerative Colitis 6/20/2014 8:26:48 AM
VBL Therapeutics Announces Novel Mechanistic Data For VB-201 – A First In Class Orally Available Anti-Inflammatory Compound That Inhibits CD14-TLR4 And TLR2-Dependent Innate Cell Activation 12/6/2013 9:03:27 AM
VBL Therapeutics Receives FDA Fast Track Designation For Lead Compound VB-111 11/27/2013 9:51:34 AM
VBL Therapeutics To Host A Satellite Symposium On VB-111, A Novel Drug For Recurrent GBM At The 2013 Scientific Meeting Of The Society For Neuro-Oncology 11/19/2013 6:30:07 AM
VBL Therapeutics Discloses Data About VB-201 Novel Mechanism and Pre-Clinical Efficacy in Atherosclerosis 7/8/2013 10:12:52 AM
VBL Therapeutics Release: Phase I/II Data of VB-111 Demonstrate Anti-Tumor Effects With Increase in Overall Survival with This Anti-Angiogenic Gene Therapy, in Patients With Recurrent Glioblastoma Multiforme 6/3/2013 12:31:20 PM
VBL Therapeutics Release: Phase I/II Data of VB-111 Demonstrate Anti-Tumor Effects With Increase in Overall Survival With This Anti-Angiogenic Gene Therapy, in Patients With Recurrent Glioblastoma Multiforme 6/3/2013 10:21:51 AM
Successful Phase One Demonstrates Tumor Response With Increased Overall Survival for Lead VBL Therapeutics Compound in Cancer 5/16/2013 12:01:38 PM
1234
//-->